{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"The number of participants with ovarian cancer whose levels of CA125 Antigen had increased since the end of the base trial are presented.","groups":[{"description":"Tisotumab vedotin was administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (once every 3 weeks). The trial ran until the investigator determined that the participant was no longer benefiting from treatment (ie, disease progression or unacceptable toxicity had occurred), the trial was terminated by the sponsor, or the participant withdrew consent. Each participant received the same dose that they were exposed to in the previous base trial.","id":"OG000","title":"Tisotumab Vedotin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 1 to Week 24 plus 30 days","title":"Number of Participants With Increased Cancer Antigen (CA 125) Levels","type":"SECONDARY","unitOfMeasure":"Participants"}